Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Javier Sanchez Alvarez

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Liver Cancer|May 31, 2022
Reply to Rizzo et alArndt Vogel, Javier Sanchez Alvarez, Monica Daigl, et al.
Oncology and Therapy|October 18, 2023
Multiple Real-World Data Sources in a Bayesian Framework to Inform Long-Term Survival Estimates of Mosunetuzumab in Patients with Follicular LymphomaJavier Sanchez Alvarez, Mahmoud Jaber, Marie-Hélène Blanchet Zumofen
Journal of Medical Economics|May 7, 2024
Cost-effectiveness analysis of mosunetuzumab for treatment of relapsed or refractory follicular lymphoma after two or more lines of systemic therapy in the United StatesMatthew Matasar, Javier Sanchez Alvarez, Hélène Parisé, et al.
Liver Cancer|December 7, 2023
Atezolizumab in Combination with Bevacizumab for the Management of Patients with Hepatocellular Carcinoma in the First-Line Setting: Systematic Literature Review and Meta-AnalysisArndt Vogel, Richard S Finn, Marie-Hélène Blanchet Zumofen, et al.
Liver Cancer|July 9, 2021
Comparative Efficacy of Atezolizumab plus Bevacizumab and Other Treatment Options for Patients with Unresectable Hepatocellular Carcinoma: A Network Meta-AnalysisArndt Vogel, Lorenza Rimassa, Hui-Chan Sun, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Liver Cancer|May 31, 2022
Reply to Rizzo et alArndt Vogel, Javier Sanchez Alvarez, Monica Daigl, et al.
Oncology and Therapy|October 18, 2023
Multiple Real-World Data Sources in a Bayesian Framework to Inform Long-Term Survival Estimates of Mosunetuzumab in Patients with Follicular LymphomaJavier Sanchez Alvarez, Mahmoud Jaber, Marie-Hélène Blanchet Zumofen
Journal of Medical Economics|May 7, 2024
Cost-effectiveness analysis of mosunetuzumab for treatment of relapsed or refractory follicular lymphoma after two or more lines of systemic therapy in the United StatesMatthew Matasar, Javier Sanchez Alvarez, Hélène Parisé, et al.
Liver Cancer|December 7, 2023
Atezolizumab in Combination with Bevacizumab for the Management of Patients with Hepatocellular Carcinoma in the First-Line Setting: Systematic Literature Review and Meta-AnalysisArndt Vogel, Richard S Finn, Marie-Hélène Blanchet Zumofen, et al.
Liver Cancer|July 9, 2021
Comparative Efficacy of Atezolizumab plus Bevacizumab and Other Treatment Options for Patients with Unresectable Hepatocellular Carcinoma: A Network Meta-AnalysisArndt Vogel, Lorenza Rimassa, Hui-Chan Sun, et al.
Pageof 1